{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-031920","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2026-07-02T20:30:32+00:00","discovered_at":"2026-07-02T20:32:01.191204+00:00","generated_at":"2026-07-02T20:32:06.559281+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Ernexa Therapeutics shareholders elect directors, ratify auditor, approve 2026 equity plan","bullets":["All five director nominees elected: Bristol, Cicala, Luther, Ratner, Wexler; broker non-votes 161,165.","Ratification of Haskell & White LLP as auditor for FY 2026: 590,236 for, 29,010 against, 495 abstentions.","Approval of 2026 Omnibus Equity Incentive Plan: 363,640 for, 94,840 against, 96 abstentions, 161,165 broker non-votes.","Quorum of 53.13% (619,741 of 1,166,333 shares) represented at the July 1, 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-031920","json":"https://secwatch.observer/filing/0001493152-26-031920.json","markdown":"https://secwatch.observer/filing/0001493152-26-031920.md","text":"https://secwatch.observer/filing/0001493152-26-031920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/0001493152-26-031920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T20:32:06.559281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}